Coloplast AS (LTS:0QBO) Cyclically Adjusted Revenue per Share: kr110.05 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QBO Coloplast AS LTS:0QBO
66 GF Score
Price kr418.40
GF Value kr809.60
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Coloplast AS Cyclically Adjusted Revenue per Share?

Coloplast AS LTS:0QBO -0.31% 66 Cyclically Adjusted Revenue per Share is kr110.05 as of Jun. 2026. GuruFocus rates LTS:0QBO with a GF Score™ of 66/100 and a GF Value™ of kr809.60 (Significantly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Coloplast AS's adjusted revenue per share for the three months ended in Jun. 2026 was kr32.635. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr110.05 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Coloplast AS's average Cyclically Adjusted Revenue Growth Rate was 6.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Coloplast AS was 10.30% per year. The lowest was 5.60% per year. And the median was 8.45% per year.

As of today (2026-09-16), Coloplast AS's current stock price is kr418.40. Coloplast AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr110.05. Coloplast AS's Cyclically Adjusted PS Ratio of today is 3.80.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Coloplast AS was 16.78. The lowest was 3.52. And the median was 9.77.


Coloplast AS  (LTS:0QBO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Coloplast AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=418.40/110.05
=3.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Coloplast AS was 16.78. The lowest was 3.52. And the median was 9.77.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Coloplast AS Cyclically Adjusted Revenue per Share Related Terms


Coloplast AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Coloplast AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coloplast AS Cyclically Adjusted Revenue per Share Chart

Coloplast AS Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.07 85.91 91.62 97.86 104.46

Coloplast AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.78 105.56 106.26 107.76 110.05

LTS:0QBO vs ISRG, BDX, RMD: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Coloplast AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coloplast AS Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Coloplast AS's Cyclically Adjusted PS Ratio falls into.


LTS:0QBO
66GF Score
Coloplast AS LTS:0QBO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coloplast AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Coloplast AS's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=32.635/122.9500*122.9500
=32.635

Current CPI (Jun. 2026) = 122.9500.

Coloplast AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 17.670 100.200 21.682
201612 17.703 100.300 21.701
201703 18.259 101.200 22.183
201706 18.427 101.200 22.387
201709 18.718 101.800 22.607
201712 18.597 101.300 22.572
201803 18.988 101.700 22.956
201806 19.920 102.300 23.941
201809 19.927 102.400 23.926
201812 20.319 102.100 24.468
201903 20.604 102.900 24.619
201906 21.617 102.900 25.829
201909 21.663 102.900 25.884
201912 22.093 102.900 26.398
202003 22.601 103.300 26.900
202006 20.699 103.200 24.660
202009 21.517 103.500 25.561
202012 22.230 103.400 26.433
202103 22.293 104.300 26.279
202106 22.671 105.000 26.547
202109 23.917 105.800 27.794
202112 24.239 106.600 27.957
202203 25.826 109.900 28.893
202206 27.498 113.600 29.761
202209 28.539 116.400 30.145
202212 28.742 115.900 30.490
202303 28.536 117.300 29.910
202306 28.715 116.400 30.331
202309 27.713 117.400 29.023
202312 30.233 116.700 31.852
202403 29.310 118.400 30.436
202406 30.627 118.500 31.777
202409 30.902 118.900 31.955
202412 31.185 118.900 32.247
202503 30.745 120.200 31.448
202506 30.870 120.700 31.445
202509 30.883 121.600 31.226
202512 31.251 121.180 31.707
202603 31.433 121.670 31.764
202606 32.635 122.950 32.635

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr110.05 mean?
Coloplast AS (LTS:0QBO) has a Cyclically Adjusted Revenue per Share of kr110.05 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Cyclically Adjusted Revenue per Share too high?
Coloplast AS's current Cyclically Adjusted Revenue per Share is kr110.05. Overall, Coloplast AS has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Coloplast AS's Cyclically Adjusted Revenue per Share of kr110.05 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Coloplast AS and its competitors. Coloplast AS's current Cyclically Adjusted Revenue per Share is kr110.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (LTS:0QBO) is currently considered Significantly Undervalued. The stock's GF Value™ is kr809.60, compared to a current price of kr418.40 — trading 48.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr110.05. Coloplast AS's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Coloplast AS (LTS:0QBO), the current Cyclically Adjusted Revenue per Share is kr110.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coloplast AS (LTS:0QBO) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of kr418.40 is trading 48.3% below its estimated GF Value™ of kr809.60. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for LTS:0QBO:

  • Cyclically Adjusted Revenue per Share: kr110.05
  • GF Value™: kr809.60 vs. price of kr418.40 (48.3% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the LTS:0QBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
66GF Score

Get the complete analysis for LTS:0QBO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr418.40
Price
kr809.60
GF Value